Clozapine-related Immunodeficiency in Parkinsons Disease

Exclusion Criteria

• •Patients with a contraindication to the use of Clozapine according to the summary of product characteristics (SPC)
• •Hypersensitivity to the active substance or to any of the excipients.
• •Patients who cannot receive regular blood tests.
• •History of granulopenia or toxic or idiosyncratic agranulocytosis (unless it results from previous chemotherapy).
• •History of agranulocytosis induced by CLOZAPINE
• •Treatment with CLOZAPINE should not be started at the same time as substances known to have a high potential for inducing agranulocytosis; The concomitant administration of depot antipsychotics is not recommended.
• •Functional bone marrow failure.
• •Uncontrolled epilepsy.
• •Alcoholic or induced psychosis, drug intoxication, comatose states.
• •Circulatory collapse and / or CNS depression regardless of the aetiology.
• •Severe renal or cardiac disorders (eg: myocarditis).
• •Active liver disease with nausea, anorexia or jaundice; progressive liver disease, liver failure.
• •Paralytic ileus.
• •Patient with another potential cause of immunosuppression
• •Immunosuppressive or immune modulatory treatment active or stopped for less than 5 years
• •Anti-epileptic treatment active or stopped for less than 5 years
• •Chemotherapy active or stopped for less than 5 years
• •Solid or hematologic cancer active or treated for less than 5 years
• •Human immunodeficiency virus infection
• •Already known constitutional immune deficiency
• •Nephrotic syndrome
• •Protein-losing enteropathy
• •A history of radiotherapy
• •Long-term use of corticosteroids
• •Patient with potentially major cognitive disorders defined by a MoCA score less than or equal to 23
• •Pregnant or breastfeeding women
• •Patient under guardianship/curatorship or deprived of liberty